263 related articles for article (PubMed ID: 37620552)
1. Evolutionary determinants of curability in cancer.
Mansur MB; deSouza NM; Natrajan R; Abegglen LM; Schiffman JD; Greaves M
Nat Ecol Evol; 2023 Nov; 7(11):1761-1770. PubMed ID: 37620552
[TBL] [Abstract][Full Text] [Related]
2. Convergent TP53 loss and evolvability in cancer.
Mansur MB; Greaves M
BMC Ecol Evol; 2023 Sep; 23(1):54. PubMed ID: 37743495
[TBL] [Abstract][Full Text] [Related]
3. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
4. p53 mutations associated with aging-related rise in cancer incidence rates.
Richardson RB
Cell Cycle; 2013 Aug; 12(15):2468-78. PubMed ID: 23839036
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics, natural history and the demise of childhood leukaemia.
Greaves M
Eur J Cancer; 1999 Feb; 35(2):173-85. PubMed ID: 10448256
[TBL] [Abstract][Full Text] [Related]
6. Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.
Xia Y; Li X; Sun W
Curr Gene Ther; 2020; 20(2):127-141. PubMed ID: 32951572
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics, natural history and the demise of childhood leukaemia.
Greaves M
Eur J Cancer; 1999 Dec; 35(14):1941-53. PubMed ID: 10711237
[TBL] [Abstract][Full Text] [Related]
8. p73 isoforms meet evolution of metastasis.
Logotheti S; Pavlopoulou A; Marquardt S; Takan I; Georgakilas AG; Stiewe T
Cancer Metastasis Rev; 2022 Dec; 41(4):853-869. PubMed ID: 35948758
[TBL] [Abstract][Full Text] [Related]
9. Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
[TBL] [Abstract][Full Text] [Related]
10. TP53: a key gene in human cancer.
Guimaraes DP; Hainaut P
Biochimie; 2002 Jan; 84(1):83-93. PubMed ID: 11900880
[TBL] [Abstract][Full Text] [Related]
11. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
12. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
13. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
14. Tumor hypoxia, p53, and prognosis in cervical cancers.
Haensgen G; Krause U; Becker A; Stadler P; Lautenschlaeger C; Wohlrab W; Rath FW; Molls M; Dunst J
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):865-72. PubMed ID: 11429213
[TBL] [Abstract][Full Text] [Related]
15. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
[TBL] [Abstract][Full Text] [Related]
16. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
17. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil).
Savio AL; da Silva GN; de Camargo EA; Salvadori DM
Mutat Res; 2014 Apr; 762():40-6. PubMed ID: 24625788
[TBL] [Abstract][Full Text] [Related]
19. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Liu C; Banister CE; Buckhaults PJ
Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
[TBL] [Abstract][Full Text] [Related]
20. The Role of
Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
